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Abstract
Background: The case fatality for intentional self-poisoning in rural Asia is 10–30 times higher
than in the West, mostly due to the use of highly toxic poisons. Activated charcoal is a widely
available intervention that may – if given early – bind to poisons in the stomach and prevent their
absorption. Current guidelines recommend giving a single dose of charcoal (SDAC) if patients
arrive within an hour of ingestion. Multiple doses (MDAC) may increase poison elimination at a
later time by interrupting any enterohepatic or enterovascular circulations. The effectiveness of
SDAC or MDAC is unknown. Since most patients present to hospital after one hour, we
considered MDAC to have a higher likelihood of clinical benefit and set up a study to compare
MDAC with no charcoal. A third arm of SDAC was added to help determine whether any benefit
noted from MDAC resulted from the first dose or all doses.
Methods/design: We set up a randomised controlled trial assessing the effectiveness of
superactivated charcoal in unselected adult self-poisoning patients admitted to the adult medical
wards of three Sri Lankan secondary hospitals. Patients were randomised to standard treatment or
standard treatment plus either a single 50 g dose of superactivated charcoal dissolved in 300 ml of
water or six doses every four hours. All patients with a history of poison ingestion were
approached concerning the study and written informed consent taken from each patient, or their
relative (for unconscious patients or those <16 yrs), recruited to the study. The exclusion criteria
were: age under 14 yrs; prior treatment with activated charcoal during this poisoning episode;
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BMC Emergency Medicine 2007, 7:2 http://www.biomedcentral.com/1471-227X/7/2pregnancy; ingestion of a corrosive or hydrocarbon; requirement for oral medication; inability of
the medical staff to intubate the patient with a Glasgow Coma Score <13; presentation >72 hrs
post-ingestion, and previous recruitment. The primary outcome was in-hospital mortality;
secondary outcomes included the occurrence of serious complications (need for intubation, time
requiring assisted ventilation, fits, cardiac dysrhythmias). Analysis will be on an intention-to-treat
basis; the effects of reported time to treatment after poisoning and status on admission will also be
assessed.
Discussion: This trial will provide important information on the effectiveness of both single and
multiple dose activated charcoal in the forms of poisoning commonly seen in rural Asia. If charcoal
is found to be effective, it should be possible to make it widely available across rural Asia in an
affordable formulation.
Trial registration: Current Controlled Trials ISRCTN02920054
Background
Deliberate self-poisoning is a major clinical problem in
many parts of the developing world where highly toxic
poisons and sparse medical facilities ensure a high fatality
rate [1,2]. Pesticides are the major problem – the WHO
estimates that they cause more than 220,000 deaths glo-
bally each year, of which most are due to organophospho-
rus (OP) insecticides [3]. But other poisons, in particular
plants, other pesticides, and some pharmaceuticals are
locally important problems [1].
Self-poisoning is particularly important in Sri Lanka
where thousands of people die each year and preventing
suicide has become a national public health priority [4,5].
The case fatality for self-poisoning in Sri Lanka is around
10%[1] but increases to over 50% for some pesticides [6].
More effective medical management is urgently required
[7,8].
Current management of self-poisoning involves resuscita-
tion and stabilisation of the patient, administration of
antidotes where available, and gastric decontamination
[9]. Mechanical forced emesis and gastric lavage are rou-
tinely used in Sri Lanka and other parts of Asia, despite lit-
tle evidence for benefit [10,11]. Activated charcoal is
available in some hospitals but is not routinely used in all,
due to doubts about its effectiveness.
Animal and simulated human overdose studies have
shown that a single dose of activated charcoal, if given
soon after a poison is ingested, can reduce absorption of
the poison [12]. The ability of charcoal to prevent absorp-
tion of poison falls off rapidly within one hour. Multi-
dose regimens of charcoal may be effective much later for
some poisons since the presence of activated charcoal in
the intestine will interrupt the enterohepatic circulation
[13,14] and may also draw poison out of the gut vascula-
ture into the bowel [15].
At the time this RCT was designed, there had been no
human studies of activated charcoal with clinically rele-
vant outcomes. During 1997 and 1999, the American
Academy of Clinical Toxicology and European Associa-
tion of Poisons Centres and Clinical Toxicologists pub-
lished reviews assessing the value of both single and
multiple dose regimens of activated charcoal in acute poi-
soning [12,14]. Each position statement noted that they
had been unable to find high quality studies with which
to assess the clinical benefit of activated charcoal. The
reports stressed the importance of establishing high qual-
ity RCTs with clinically relevant outcomes in order to
determine the role of these interventions in poisoning
management. The evidence for clinical benefit from a sin-
gle dose of activated charcoal was again reviewed in 2004,
but no new trials were reported [16].
We further carried out a Clinical Evidence search and
appraisals in 2001 (and annually thereafter), together
with systematic review of Medline, Embase, and Cochrane
Collaboration databases, plus discussion with experts in
the field, to identify relevant RCTs looking at activated
charcoal in acute self-poisonings before starting our RCT
[17]. We were unable to find any studies that were not dis-
cussed in the above reviews.
After this RCT started, two controlled studies of a single
dose of activated charcoal in poisoning with pharmaceu-
ticals were reported from the USA[18] and Australia [19].
Both used a primary outcome of length of hospital stay
rather than a clinical outcome. The former study recruited
1479 patients but did not randomize them, instead using
an 'even-odd day' system for allocation. A problem with
this method is shown by the very different numbers of
patients allocated to each arm, drawing doubt on the con-
clusion that activated charcoal had no effect. The latter
study randomised 327 patients and found no difference
between patients receiving charcoal and those receivingPage 2 of 8
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patients seen in Sri Lanka.
15 months into the trial, a 400 patient RCT was published
that reported benefit from 12 doses of activated charcoal
in yellow oleander poisoning [20], a poison ingested by
around 30% of patients in our RCT. After review of the
published RCT and the results of an interim analysis of
595 oleander poisoned patients receiving either SDAC or
MDAC in this trial, the IDMEC decided that it was impor-
tant to obtain independent verification of the first study's
result, and recommended that the trial continue.
We set up this RCT in Sri Lanka in early 2002 and recruited
the first patient on the 31st March 2002. The study was
stopped in October 2004 after the final interim analysis
with more than 4500 patients recruited. The final data
analysis is underway and should be reported during 2007.
Methods/design
The study was designed as an open RCT with three parallel
groups: multiple dose charcoal vs single dose charcoal vs
no charcoal in Sri Lankan adult patients presenting to a
secondary hospital with a history of acute self-poisoning.
From May 2004, an RCT of pralidoxime in symptomatic
organophosphorus pesticide poisoned patients
(ISRCTN55264358) was nested into this study.
The principal research question to be addressed was
whether activated charcoal, either as a single or multi-
dose regimen, will reduce the rate of death and complica-
tions following acute poisoning.
The trials were drawn up using the MRC's clinical trial pro-
forma and were designed to be compliant with the CON-
SORT statement [21].
Patients
The RCT was performed in Anuradhapura and Polon-
naruwa General Hospitals, the secondary referral hospi-
tals in North Central Province, and in Kurunegala
Teaching Hospital, the secondary referral hospital for
much of the North Western province and a tertiary referral
hospital for areas further north.
All patients with a history of poison ingestion were
approached concerning the study. Written informed con-
sent was requested from conscious patients by a study
physician in the patient's own language. For patients
between 14 and 16 years, written informed consent was
obtained from the patient's parents/guardian. As
requested by the Faculty of Medicine Ethics Committee
(see below), consent for unconscious adult patients was
sought from accompanying relatives. Patients under the
age of 16 or unconscious on admission and without any
relatives were not recruited to the trial.
Patients who do not give consent to recruitment received
usual care from the medical ward staff. Their progress was
monitored at each ward round but the study team was not
involved in their care.
Inclusion and exclusion criteria
The study aimed to recruit all patients admitted to the
adult medical wards of the study hospitals with a history
of acute oral self-poisoning. Exclusion criteria were: age
under 14 yrs (lower age of patients admitted to Sri Lankan
adult medical wards); prior treatment with activated char-
coal during this episode of poisoning; known pregnancy;
ingestion of a corrosive; ingestion of a hydrocarbon alone;
requirement for oral medication; inability of the medical
staff to intubate the patient with Glasgow Coma Score
(GCS) <13; presentation >72 hrs post-ingestion, and pre-
vious recruitment to the RCT. The last four exclusion cri-
teria were added to the protocol in an amendment
submitted to the ethics committee in May 2002.
Patient management
All patients are seen on admission to the medical wards
or, in Kurunegala, after admission to the Emergency Treat-
ment Unit (emergency department). There the patients
were resuscitated as necessary by wards doctors together
with study doctors. The patient's airway was stabilised and
oxygen, atropine, fluids, and antidotes given as necessary.
Gastric decontamination was only started when patients
were stable. The original protocol stated that patients
would receive neither gastric lavage nor forced emesis.
However, at the request of the consultant physicians car-
ing for the patients, from June 2003 patients who pre-
sented within two hours of ingestion of a potentially
serious poison received a brief gastric lavage (3 × 300 ml
of water). Many patients received either gastric lavage or
mechanical forced emesis in the peripheral hospital trans-
ferring the patient before admission to the study hospi-
tals.
Patients remained under the care of the hospitals' consult-
ant physicians using management protocols agreed
between the consultants and study team [22]. The ward
medical teams made decisions about intubation and
transfer of patients to intensive care or for cardiac pacing
independently of study doctors. All decisions were made
on the basis of clinical condition and do not reflect the
poison ingested or the charcoal allocation.
Patients were seen regularly by full time study doctors at
least every three hours and more often according to clini-
cal need, 24 hrs a day. Patients were also seen on a studyPage 3 of 8
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their condition was recorded in a handheld computer
using a specially written database. Significant events
(intubation, seizures, death) were recorded at the time of
the event. The patients' condition over the previous 12 hrs
was reviewed at each ward round.
Patients were first managed on the medical ward. Seri-
ously ill patients, as judged by the medical team, were
then transferred to the intensive care unit (ICU) as a bed
became available. Each hospital had 2–8 ICU beds for
medical patients; many were filled with OP poisoned
patients and there was usually a delay in obtaining a bed.
Criteria for intubation included tidal volume less than
180 ml/breath using a Wright's respirometer, respiratory
rate of less than 10 breaths/minute, abdominal breathing,
or failure of non-invasive methods to maintain a patent
airway. Arterial blood gas measurements were not availa-
ble to guide therapy. Hypotensive patients, unresponsive
to atropine and fluid resuscitation, were treated with
dopamine plus dobutamine as necessary (these were the
only inotropes available in the hospitals).
Trial interventions and study procedures
Patients randomised to single or multiple dose activated
charcoal regimens ingested 50 g of superactivated char-
coal (Carbomix BP, Norit, NL; 2000 m2/g) in 300 ml of
water (without sorbitol or mannitol) soon after recruit-
ment. Patients receiving multiple doses subsequently
ingested another five doses of 50 g charcoal at four hour
intervals. The original RCT protocol proposed administer-
ing 18 doses of charcoal every 4 hours over 3 days. Early
experience in the study demonstrated the immense diffi-
culty of giving so many doses to patients (in particular
gaining the patient's acceptance) and the number of doses
was reduced to six in an amendment sent to the ethics
committees in May 2002.
Alert patients drank the charcoal; patients with reduced
consciousness received the charcoal via a nasogastric tube.
Control patients did not receive activated charcoal. All
patients were kept well hydrated to reduce the risk of
intestinal blockage with the charcoal and monitored reg-
ularly throughout their time on the medical ward.
Patients were followed up until final hospital discharge or
transfer to a psychiatric ward.
We did not expect a major problem with compliance since
the charcoal was given by the study team while the patient
was under supervision in hospital. Unconscious patients
received the charcoal by nasogastric tube after intubation.
Conscious patients were actively encouraged to drink the
charcoal by the study team; however, patients were not
forced in any way to take the charcoal.
A 10 ml blood sample was taken using a sterile syringe
and needle from each patient on recruitment. Further 5 ml
blood samples were taken at one, four and twelve hours
post-treatment, and then at daily intervals until discharge
or death. Whether a needle or indwelling cannula was
used was determined by the wishes of the patient. The
identity and blood concentration of the poison was
assayed retrospectively in only a subset of patients due to
limited laboratory facilities.
Randomisation
Patients were randomised into one of three study arms.
The random allocation sequence was generated by com-
puter and incorporated into a Microsoft Access pro-
gramme written for patient recruitment, randomisation
and event recording (Figure 1). Stratified block randomi-
sation was performed using the following strata: (i) the
toxin stated to have been ingested (oleander, organophos-
phate or carbamate, organochlorine, other pesticide or
unknown pesticide or paraquat, medicine or unknown) ;
(ii) reported time between poisoning and recruitment (<1
hr; 1–4 hrs; >4 hrs; unknown); and (iii) status on admis-
sion (Asymptomatic, Symptomatic with GCS 14 or 15/15,
Symptomatic with GCS <14).
The allocation sequences were generated independently
by the study statistician (EJ) and implemented by the pro-
grammer (SA), neither of whom had a role in patient
recruitment, treatment or assessment. Variable block sizes
of 3, 6 and 9 were used to allocate patients in equal num-
bers to each treatment group i.e. ratio 1:1:1 using Stata v7
software (ralloc subroutine version 3.2.5).
Participants were recruited and randomised by a study
doctor at the bedside using a dedicated handheld compu-
ter at each study hospital (Figure 1). Randomisation
The hand held computer used to recruit and randomise patients and to record all even sFigure 1
The hand held computer used to recruit and randomise 
patients and to record all events. Randomisation was per-
formed at the patient's bedside. Allocation could not be pre-
dicted by the study doctor.Page 4 of 8
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and receipt of consent noted, and could not be manipu-
lated by study doctors. The recruiting doctor was unable
to predict allocation before randomisation.
All practical steps were taken to avoid bias: (i) the ran-
domisation program was designed to be rapid and simple
to operate, and yet remain independent of the investiga-
tors; (ii) the next treatment allocation could not be pre-
dicted in advance; (iii) the primary outcome, vital status
at discharge, was unambiguous, and the secondary out-
comes were objective; (iv) all outcomes were recorded sys-
tematically by the study team, not other hospital
physicians; (v) patient follow-up was expected to be near
100% complete; and (vi) the analysis will be performed
on an intention-to-treat basis.
Outcomes
The primary outcome was all-cause mortality during hos-
pital admission.
Secondary outcomes were identified a priori as relevant to
specific poisons since different complications were
expected according to the poison ingested. For pesticides,
secondary outcomes included: (i) proportion of patients
requiring intubation; (ii) total period of time ventilated;
(iii) time to first ventilation; and (iv) seizures. For yellow
oleander poisoning, the secondary outcome was the pro-
portion of patients with cardiac dysrhythmias requiring
anti-digoxin Fab (indications: 3° heart block, Mobitz type
II 2° block, sinus bradycardia with heart rate <35 bpm,
and sinus arrest or block with sinus pauses >3 secs) or
serum potassium greater than 6.0 [23]. Unfortunately,
anti-digoxin Fab became unavailable after four months
[24] and patients were then transferred to tertiary cardiac
centres for temporary pacing. Transfer used the same cri-
teria and therefore this secondary outcome become a
combination of receiving anti-digoxin Fab or transfer for
tertiary care.
All secondary outcomes were reviewed twice a day at the
review ward rounds. Any events not recorded at the time
they occurred were recorded at this ward round.
Sample size
In both hospitals, at least 10% of poisoned patients die
before discharge [1]. An absolute reduction of 3% will be
clinically important. In order to be able to detect whether
either regimen of activated charcoal reduced the death
rate from 10% to 7%, with a significance level (alpha) of
5% and a power of 80%, a minimum of 1400 patients had
to be recruited to each arm of the trial (i.e. 4,200 patients
in total).
Sample size calculations were based on current practice
and a case fatality rate of 10%. The Independent Data
Monitoring and Ethics Committee (IDMEC) was asked to
review the recruitment and event rates during the first year
of the trial in order to make recommendations about
expanding the trial by including further hospitals if neces-
sary.
There should have been no loss to follow up for the pri-
mary outcome. Patients were either discharged alive from
the wards or their bodies transferred to the morgue for
judicial autopsy. All secondary outcomes were assessed in
hospital before discharge.
Study hypotheses and principal comparisons
The main hypothesis is that multi-dose activated charcoal
will reduce the case fatality rate from 10% to 7%, hence
the first principal comparison will be multi-dose activated
charcoal versus no intervention. The potential of multi-
dose regimens to work long after ingestion – due to inter-
ruption of enterohepatic circulation and gut dialysis –
means that such a regimen is more likely to work in a sit-
uation where people typically present several hours after
ingestion.
We suspected that a single dose of charcoal would be less
effective since most poison absorption will have taken
place by the time the patients present to hospital. There-
fore, the second principal comparison will test the
hypothesis that the case fatality rate in patients receiving a
single dose of activated charcoal is equal to that in
patients receiving multiple doses.
In order to investigate whether a single dose of activated
charcoal has a similar effect as giving no intervention, the
third principal comparison will test the hypothesis that
the case fatality rate in patients receiving a single dose of
activated charcoal is equal to that in patients receiving no
intervention.
Statistical analysis
The main analysis will be carried out on an intention-to-
treat basis, using the chi -squared test for the primary out-
come (or Fisher's exact test if appropriate) and for other
dichotomous outcomes. Odds ratios (plus 95% confi-
dence intervals) will be reported to establish magnitude
and direction of the treatment effect. In the original pro-
tocol, we indicated that risk would be the chosen measure
of effect; however, in order to be able to adjust the treat-
ment effect estimate for stratification variables in future
analyses, we will calculate odds instead, using logistic
regression. Since the primary outcome is an uncommon
event, risk and odds should be similar.Page 5 of 8
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the logrank test to compare treatment groups, produce
Kaplan-Meier curves to illustrate the comparison, calcu-
late incidence rates and perform Cox's regression to esti-
mate hazard ratios, adjusted for stratification factors.
An analysis of trends in treatment effect for factors
'reported time from ingestion to treatment' and 'patient
status on admission' will be performed.
It is possible that both treatment regimens, if effective in
reducing case fatality rates, will be more effective the ear-
lier they are started. Therefore we will assess the trends in
clinical effectiveness according to time post-ingestion to
start of therapy using statistical modelling techniques. In
order to determine whether treatment should be started
irrespective of severity, we will likewise also assess trends
in case fatality rates across a gradient of severity.
Admission blood samples will be retrospectively analysed
to determine the identity of the poison ingested. The pri-
mary analyses will be repeated using the confirmed iden-
tity of the poison.
Pre-specified subgroup analysis
Subgroup analyses are planned to look at the consistency
of treatment effect across different types of poison sus-
pected/reported to be ingested, time since ingestion and
severity. Poison subgroups investigated will include orga-
nophosphorus pesticides, oleander, other or unknown
pesticide' and paraquat, and other/medicine poisonings.
A further subgroup of organophosphorus poisonings, die-
thyl versus dimethyl versus unknown will also be investi-
gated. These subgroup analyses will use the test of
interaction (or test for trend) and will be carried out for
the primary outcome only.
Independent Data Monitoring and Ethics Committee 
(IDMEC)
An independent IDMEC was established for the trial. For
the duration of recruitment, interim analyses were sup-
plied by the trial statistician (EJ), in strict confidence, to
the Chair of the IDMEC, together with any other analyses
the IDMEC requested. Meetings were arranged periodi-
cally, as considered appropriate by the Chair. In the light
of interim data, and other evidence from relevant studies,
the IDMEC was to inform the principal investigator (Dr
Michael Eddleston), if in their view (i) there was proof
beyond reasonable doubt that the data indicated that any
part of the protocol under investigation was clearly indi-
cated or contra-indicated, either for all participants or for
a particular subgroup of trial participants, or (ii) it was
evident that no clear outcome would be obtained.
The decision to inform the principal investigator in either
of these circumstances was, in part, based on statistical
considerations. Appropriate criteria for proof beyond rea-
sonable doubt were not specified precisely. A difference of
at least three standard deviations in the interim analysis of
the major endpoint might be needed to justify halting, or
modifying, such a study prematurely. If this criterion were
to be adopted, it would have the practical advantage that
the exact number of interim analyses would be of little
importance, and so no fixed schedule is proposed [25].
Unless modification or cessation of the protocol was rec-
ommended by the IDMEC, the principal investigator, co-
investigators, collaborators and administrative staff were
to remain ignorant of the results of the interim analyses.
Collaborators and all others associated with the study
could write to the Chair of the IDMEC to draw attention
to any concern they may have about the possibility of
harm arising from the treatment under study, or any other
matter that may be relevant. The principle investigator
would follow the advice of the Chairman concerning deci-
sions to continue or stop the trial.
The members of the IDMEC for this study were:
Dr Mike Clarke, Cochrane Collaboration, Oxford, UK
(Chairman).
Dr Julian Higgins, MRC Biostatistics Unit, Cambridge, UK
(Statistician).
Professor Keith Hawton, Dept Psychiatry, Oxford Univer-
sity, UK.
Professor Saroj Jayasinghe, Dept Medicine, Colombo Uni-
versity, Sri Lanka.
Professor Nimal Senanayake, Dept Medicine, Peradeniya
University, Sri Lanka.
Professor Krisantha Weerasuriya, SEARO/WHO, Delhi,
India.
Ethics
Ethics approval was received from the Oxfordshire Clini-
cal Research Ethics Committee, UK (application number
C01.120), and from the Faculty of Medicine Ethics Com-
mittee, University of Colombo, Sri Lanka (number
EC_00_77)
Discussion
If activated charcoal can be proven to be effective, then it
should be an extremely valuable therapy since it is widely
available in the developing world, relatively cheap, binds
to many poisons, and safe once the airway is protected.
Since the greatest benefit has been seen when charcoal isPage 6 of 8
(page number not for citation purposes)
BMC Emergency Medicine 2007, 7:2 http://www.biomedcentral.com/1471-227X/7/2given within 15 mins of poisoning,[12] it could be sup-
plied to villages to allow people to give charcoal to their
relatives within minutes of the poisoning and before
transfer to hospital. On the other hand, if it is found to be
ineffective, then the many thousands of dollars currently
being spent on activated charcoal across Asia could be
diverted to more effective interventions.
One major issue with this trial was that neither gastric lav-
age nor mechanical forced emesis was to be given to trial
patients, following current international practice. Recent
systematic reviews by international toxicological societies
[10,11] (updated 2004 [26,27]) were unable to find any
evidence that either gastric lavage or forced emesis with
ipecacuanha produces clinical benefit.
Human simulated overdose studies indicate that around
30% of tablets can be washed out if gastric lavage is initi-
ated within 15 mins of poisoning. However, the yield falls
off rapidly after this time [11,26]. The yield from liquid
poisons such as pesticides is likely to be even less since liq-
uids pass out of the stomach into the small bowel (and
therefore out of the reach of lavage) quicker than the tab-
lets on which most studies have been performed. This is
likely to be particularly true for OP pesticides since their
cholinergic action speeds up gastric emptying.
Serious complications such as oesophageal rupture and
aspiration occur with gastric lavage, particularly when the
procedure is performed in uncooperative conscious
patients or in unintubated unconscious patients [11,26].
Insertion of gastric lavage tubes also risks generating a
bradycardic vasovagal response, sometimes resulting in
asystole. This can be particularly severe in patients with
OP or oleander poisoning who already have poison-
induced bradycardias. An observational series of gastric
lavage in 15 Sri Lankan patients revealed 2 deaths due to
the lavage and nine cases of aspiration requiring antibiot-
ics [28]. The risks of gastric lavage in circumstances when
resources limit the ability of doctors to sedate and intu-
bate patients far outweigh the small benefits possible
from the procedure.
The use of ipecacuanha for forced emesis has been dis-
couraged due to complications of persistent vomiting in
patients at risk of rapid reductions in conscious level and
its poor return. The yield of forced emesis without ipecac-
uanha is minimal and for these reasons forced emesis of
any form is now discouraged [10,27].
After discussion, this approach was approved by both eth-
ics committees. However, some clinicians considered lav-
age to be of fundamental importance to medical
management and practice was changed after 15 months to
follow that recommended in a Sri Lankan textbook of poi-
soning. Thereafter, all patients who presented within two
hours of a serious ingestion underwent gastric lavage after
stabilisation.
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